Showing 5491-5500 of 7383 results for "".
- Tralokinumab Achieves Primary and Secondary Endpoints in Three pivotal Phase 3 Trials for ADhttps://practicaldermatology.com/news/tralokinumab-achieves-primary-and-secondary-endpoints-in-three-pivotal-phase-3-trials-for-ad/2460440/LEO Pharma A/S, shared results showing that tralokinumab 300mg, administered subcutaneously every two weeks, demonstrated efficacy and safety with or without concomitant use of a topical corticosteroid (TCS) in three Phase 3 trials (ECZTRA 1-3) for the treatment of adults with moderate to severe
- Abbvie's RINVOQ Improves Skin Clearance and Itch in First Phase 3 Study for ADhttps://practicaldermatology.com/news/abbvies-rinvoq-improves-skin-clearance-and-itch-in-first-phase-3-study-for-ad/2460439/AbbVie’s RINVOQ (upadacitinib) performed well in Measure Up 1, the first Phase 3 study to evaluate its efficacy and safety for the treatment of moderate-to-severe atopic dermatitis. Full results from Measure Up 1 will be presented at a future medical meeting and published in a pee
- Label Update: Low Risk of Antibiotic Resistance with Almirall's Seysarahttps://practicaldermatology.com/news/label-update-low-risk-of-antibiotic-resistance-with-seysara/2460437/The FDA approved a label update for Almirall's Seysara stating that P. acnes strains displayed a low propensity for the development of resistance to sarecycline. This information is included in the Microbiology Section (12.4) of the prescribing information.</
- Health Canada Approves Two New Gynecological Indications For Candela’s CO2RE Laser Platformhttps://practicaldermatology.com/news/health-canada-approves-two-new-gynecological-indications-for-candelas-co2re-laser-platform/2460434/Health Canada has approved Candela’s CO2RE laser for the treatment of genitourinary syndrome of menopause (GSM) and stress urinary incontinence (SUI) in adult women. The CO2RE laser, a single CO2 platform equipped w
- AAD Survey: Parents Get the Importance of Sunscreen for their Kidshttps://practicaldermatology.com/news/aad-survey-parents-get-the-importance-of-sunscreen-for-their-kids/2460433/Fully 74 percent of parents today worry about sun protection more with their children than their parents did with them, and 90 percent of parents believe it’s important to teach their children healthy habits now so they will keep them when they are adults, finds a new survey from the Americ
- Further Evidence of Long-term Use and Cost-effectiveness of Ilumya for Psoriasis Presented at Virtual AADhttps://practicaldermatology.com/news/further-evidence-of-long-term-use-and-cost-effectiveness-of-ilumya-for-psoriasis-presented-at-virtual-aad/2460425/Sun Pharmaceutical Industries Ltd. presented further evidence of the long-term use and cost-effectiveness of tildrakizumab-asmn (Ilumya) in moderate to severe plaque psoriasis at the American Academy of Dermatology (AAD) Virtual Meeting Experience 2020. Long-term analyses of the reSURFA
- Late-Breaking Data: Lilly and Dermira’s Lebrikizumab Improves Itch, Sleep and Quality of Life in ADhttps://practicaldermatology.com/news/late-breaking-data-lilly-and-dermiras-lebrikizumab-improves-itch-sleep-and-quality-of-life-in-ad-1/2460424/Lilly and Dermira’s Lebrikizumab improves itch, sleep and quality of life in patients with moderate-to-severe atopic dermatitis (AD), according to a Phase 2b clinical trial presented during a virtual late-breaking, oral session at the American Academy of Dermatology (AAD) 2020 Annual Meetin
- Late-Breaking Data: Skyrizi Achieves Superior Rates of Complete Skin Clearance for Psoriasis Compared to Secukinumab at 52 Weekshttps://practicaldermatology.com/news/late-breaking-data-show-skyrizi-achieves-superior-rates-of-complete-skin-clearance-for-psoriasis-compared-to-secukinumab-at-52-weeks/2460423/New late-breaking Phase 3b head-to-head data show superior rates of skin clearance for AbbVie's risankizumab-rzaa (Skyrizi) compared to secukinumab (Cosentyx) at week 52. Sixty-six percent of psoriasis patients receiving Skyrizi achieved completely clear skin—100 percent clearance in th
- Bimekizumab Phase 3 Data Show Superior Skin Clearance in Psoriasis vs. Placebo and Ustekinumabhttps://practicaldermatology.com/news/bimekizumab-phase-3-data-show-superior-skin-clearance-in-moderate-to-severe-psoriasis/2460421/UCB shared first presentations of data from the Phase 3 clinical development program of bimekizumab, its investigational IL-17A and IL-17F inhibitor, as part of a virtual session for the American Academy of Dermatology (AAD) 2020 Annual Meeting. Patients treated with bimekizumab achieved superior
- ProTransit to Target Photodamage in Trials of New Nanoparticle Technologyhttps://practicaldermatology.com/news/protransit-to-target-photodamage-in-trials-of-new-nanoparticle-technology/2460418/ProTransit Nanotherapy plans to launch human clinical trials this summer with products that could target precursors of skin cancers. The company has developed therapies based nanoparticle technology invented at the University of Nebraska Medical Center to help prevent and potentially improve suns